DJIA 17,778.15 421.28 2.43%
NASDAQ 4,748.40 104.08 2.24%
S&P 500 2,061.23 48.34 2.40%
market minute promo

Exelixis (NASDAQ: EXEL)



company name or ticker

Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results -

Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog

Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog

Exelixis' Partners File New Drug Application For Cobemetinib - Welcome News But Little Impact

3 Healthcare Stocks to Watch in 2015

These are the three healthcare stocks you need to be watching heading into next year.

Array BioPharma Advances To All Systems Go, Collects $85 Million

Exelixis' COMET-2 Failure And A Discussion Of Potential Future Cash Flow

Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog

Is Exelixis, Inc. Stock Doomed?

Small-cap biotech Exelixis has fallen hard in 2014. Could the stock rebound next year, or will it drop even further?

Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip

Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip

See More Articles...